Medtronic starts cryoballoon AF trial; WSJ reviews infant nose aspirator;

@FierceMedDev: ICYMI yesterday: Medtronic partners with LHC to provide at-home, post-acute care patient monitoring services. Article | Follow @FierceMedDev

@VarunSaxena2: FDA clears 3-D printed device for minimally invasive foot surgery. Story | Follow @VarunSaxena2

@EmilyWFierce: Scientists renewing research for psychedelics as a treatment for anxiety and depression. More from The New Yorker | Follow @EmilyWFierce

> Medtronic ($MDT) has started a 12-month, outcomes trial for its Arctic Front Advance Cryoballoon system to treat patients with early persistent atrial fibrillation (AF). Cryoablation is already available in Europe to treat AF patients and in the U.S. it is FDA-approved for patients with drug refractory, recurrent, symptomatic, paroxysmal AF. Release

> Ultrasonic spinal surgery company Misonix will buy the remaining rights from Aesculap to the Misonic BoneScalpel for an undisclosed sum. This includes hospital supply agreements of up to three years for the bone dissection tool. Release

> The Wall Street Journal reviewed an infant nasal aspirator designed for at-home use. Story (sub. req.)

> OrthAlign gained a CE mark for its OrthAlign Plus system, a palm-sized single-use positioning device for use in total hip and total knee arthroplasty surgeries. Release

Biotech News

@FierceBiotech: Cornell team engineers a probiotic GLP-1 therapy for diabetes. FierceBiotechResearch story | Follow @FierceBiotech

@JohnCFierce: Sanofi, Roche and Lilly help bankroll a $20M round for Parkinson's player LTI. Report | Follow @JohnCFierce

@DamianFierce: Biotech companies just don't close anymore. Report | Follow @DamianFierce

> Isis hails a Phase II diabetes victory, with caveats. More

> J&J teams with U.K. to probe molecular causes of RA drug failures. News

> Famed investor Mellon plans £100M fund for small biotechs. Article

Pharma News

@FiercePharma: ICYMI from FierceAnimalHealth: IDEXX raises 2015 sales forecast on predicted demand for new lab tests. Article | Follow @FiercePharma

@EricPFierce: FDA issues warning letter to a second Apotex plant in India. Data manipulation alleged again. Letter | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Shire's ADHD star Vyvanse scores FDA's first binge eating approval. Article | Follow @CarlyHFierce

> It's put up or shut up time for Sanofi and MannKind as Afrezza hits the market. More

> FDA study spanks drugmakers for poor adverse events reporting. Story

Biotech Research News

> Cleveland Clinic team posts a big target for CKD drug developers. Story

> Dartmouth team tags HER4 as a key culprit for HER2 drug resistance. More

> Johns Hopkins technique opens a new window on brain disorders. Item

> Investigators zero in on an enzyme linked to BRCA1/2 cancer mutations. Story

> Cardiac study points to new treatment to guard against arrhythmias. Article

Pharma Manufacturing News

> Vertellus completes $200M deal for Dow plant that makes sodium borohydride. Story

> Sanofi ups diabetes game in India through hospital clinics, local production. Article

> Biogen Idec expands North Carolina manufacturing operations. More

> Emerging market demand saves Irish Lipitor plant from closing. Story

> Dr. Reddy's mulling facility shift to avoid losing out on Nexium generic. Report

Suggested Articles

The FDA has cleared its first fully disposable duodenoscope, following years of reports of infections being transmitted between patients.

OR-focused AI provider Caresyntax has garnered $45.6 million in new funding and picked up a data analytics firm to broaden its footprint.

A study of Foundation Medicine’s FoundationOne liquid biopsy test found it was able to predict the risk that a person’s breast cancer would return.